EF-CAB4A Inhibitors

PI3K inhibitor that reduces phosphorylation of AKT. An inhibited AKT pathway results in decreased activation of downstream proteins that may interact with or regulate EF-CAB4A, leading to its reduced activity.

Irreversible PI3K inhibitor which suppresses AKT activation. With reduced AKT activity, proteins that govern EF-CAB4A stability or function are affected, thus diminishing EF-CAB4A activity.

mTOR inhibitor that blocks downstream signaling required for protein synthesis, possibly reducing the synthesis of proteins that associate with EF-CAB4A, thereby inhibiting EF-CAB4A's activity.

Inhibits MEK1/2, preventing ERK pathway activation. ERK normally phosphorylates substrates that could be linked to EF-CAB4A function; inhibition here would reduce EF-CAB4A activity.

p38 MAPK inhibitor which could reduce phosphorylation of substrates potentially interacting with EF-CAB4A, leading to decreased EF-CAB4A activity.

MEK inhibitor that prevents the activation of the MAPK/ERK pathway, potentially affecting proteins that regulate EF-CAB4A function, indirectly leading to its inhibition.

JNK inhibitor which might decrease the phosphorylation of JNK substrates, potentially impacting EF-CAB4A's activity through these substrate interactions.

Src family kinase inhibitor that could disrupt downstream signaling pathways, potentially leading to reduced activity of proteins that regulate EF-CAB4A.

Another Src family kinase inhibitor that could prevent activation of proteins that regulate EF-CAB4A, thereby diminishing its activity.

ROCK inhibitor that could destabilize cytoskeletal elements, potentially altering the cellular environment of EF-CAB4A and reducing its activity.